1. Adalimumab and Infliximab in Crohn's disease - real life data from a national retrospective cohort study.
- Author
-
PREDA, CARMEN, FULGER, LARISA, GHEORGHE, LIANA, GHEORGHE, C., GOLDIS, A., TRIFAN, ANCA, TANTAU, M., TANTAU, ALINA, NEGREANU, L., MANUC, M., CIJEVSCHI-PRELIPCEAN, CRISTINA, IACOB, R., TIERANU, C., MEIANU, CORINA, and DICULESCU, M.
- Subjects
ADALIMUMAB ,INFLIXIMAB ,CROHN'S disease ,RETROSPECTIVE studies ,COHORT analysis ,LOGISTIC regression analysis - Abstract
Aim: to compare the efficacy and safety of Adalimumab(ADA) and Infliximab(IFX), in a large Romanian population and to identify predictors of response. Methods We performed a national retrospective cohort study including 265 patients (136 ADA, 129 IFX) between 2008-2014. Binary logistic regression was performed with the statistical program Minitab. Results: Patients were half women, with a median age of 36, a median disease duration of 2.5 years, 80% received Azathioprine. Mean therapy duration was 20 months in ADA group and 36 months in IFX group. Complete response to Adalimumab respectively Infliximab was recorded in 77%vs.65%, secondary loss of response in 18%vs.28%, statistically comparable. We failed to identify predictors of response. In 79.2%of patients with secondary loss of response to ADA, the dose was escalated, 12.5% were switched to Infliximab. In 70%of patients that lost response to IFX, the dose was increased, 30% were switched to Adalimumab. Conclusions: Adalimumab and Infliximab have similar efficacy, with a complete response rate of~70%. In case of secondary loss of response to IFX, the best solution is to switch to ADA, with 83% response rate, while in case of secondary loss of response to ADA, increasing the dose leads to 84 % response rate. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF